Overview

Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Cttq

Treatments:

Nivolumab